Entecavir versus Lamivudine for Prevention of Liver-Related Events in Patients with HBV-Related Advanced Liver Disease: A Multicenter, Prospective Study

Park, J.Y.; Kim, S.G.; Tak, Won Young; Yim, H.J.; Jang, Boook; Kim, M.Y.; Kim, B.I.; Lee, J.-W.; Yoon, K.T.; Cheong, J.Y.; Kwon, Seog Woon; Kim, T.Y.; Bae, Sun Hyun; Seo, Yousuke; Kwon, Junyoung; Kim, D.J.; Kim, J.-K.; Jeong, Sukhyeon; Ahn, S.H.; Han, Kwang Hyub

doi:10.1016/s0168-8278(16)01097-7

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among ten studies, six compared NA-treated with untreated patients [18,19,[21][22][23][24], and four compared first-line with non-first-line NAs [5,25,26,28]. The rate of variceal bleeding was significantly lower in NA-treated than in untreated patients (RR, 0.44; 95% CI: 0.26-0.74; I 2 =82%).…”

Section: Impact On Variceal Bleedingmentioning

confidence: 99%

“…Among 25 studies, 11 compared NA-treated with untreated patients [18,[22][23][24][30][31][32][33][34][35][36], 13 compared first-line with non-first-line NAs [5,[25][26][27][28][29][37][38][39][40][41][42][43], and one provided data on both comparisons [44]. Overall, NA-treated patients showed a significantly lower risk of HCC development than untreated 10 ones (RR, 0.48; 95% CI: 0.30-0.75; I 2 = 91%).…”

Section: Impact On Hcc Developmentmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease

Kong

et al. 2022

Hepatol Int

View full text Add to dashboard Cite

Background:The efficacy of treatment with nucleos(t)ide analogues (NAs) in non-cirrhotic chronic hepatitis B (CHB) patients is well-established. However, its impact on complications of portal hypertension in advanced chronic liver disease (ACLD) is less well-characterized.Methods: MEDLINE/PubMed, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, and abstracts of major international hepatology meetings were searched for publications from Jan 1, 1995 to Nov 30, 2021. Randomized control trials and observational studies reporting the efficacy of NAs in ACLD patients were eligible. Pooled risk ratios (RRs) for outcomes of interest were calculated with a random-effect or fixed-effect model, as propriate.Results: Thirty-nine studies including 14 212 ACLD patients were included. NA treatment was associated with reduced risks of overall hepatic decompensation events (RR, 0.51; 95% confidence interval [CI]: 0.37-0.71) such as variceal bleeding (RR, 0.44; 95% CI: 0.26-0.74) and also ascites (RR, 0.10; 95% CI: 0.01-1.59) on a trend-wise level. Moreover, the risks of hepatocellular carcinoma (HCC) (RR, 0.48; 95% CI: 0.30-0.75) and liver transplantation/death (RR, 0.36; 95% CI: 0.25-0.53) were also reduced by NA treatment and first-line NAs were superior to non-first-line NAs in regard to these outcomes (RR, 0.85; 95% CI: 0.75-0.97 and RR, 0.85; 95% CI: 0.73-0.99, respectively). Conclusion:NA therapy lowers the risk of portal hypertension-related complications including variceal bleeding, as well as HCC, and liver transplantation/death.

show abstract